Physician profile
Jeffrey E Stark
NPI 1912239468
$771.18
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $129.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $91.26 | 2021 | |
| Abbvie INC. | $66.28 | 2021-2022 | |
| Astellas Pharma US INC | $61.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $59.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.16 | 2021 | |
| Xeris Pharmaceuticals, INC. | $49.73 | 2021 | |
| Amgen INC. | $26.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.83 | 2022 | |
| Lilly USA, LLC | $16.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.22 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.